Christopher Cabell - 21 Feb 2026 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Reporting relationship: President & Head of R&D
Issuer ticker: IKT
Reported as of: 21 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Feb 2026, 20:53:37 UTC
Prior SEC filing: 07 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Iwicki, attorney-in-fact

Key filing fact

Christopher Cabell filed Form 4 for Inhibikase Therapeutics, Inc. (IKT) on 24 Feb 2026.

Key facts

This page summarizes Christopher Cabell's Form 4 filing for Inhibikase Therapeutics, Inc. (IKT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Feb 2026, 20:53.

Change

Previous filing in this sequence was filed on 07 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001814928 Primary reporting owner

Cabell Christopher

Relationship: President & Head of R&D
Address: 1000 N. WEST STREET, SUITE 1200, WILMINGTON
Signature: /s/ Mark Iwicki, attorney-in-fact
Signature date: 24 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IKT transaction

Common Stock

Disposed to Issuer

Transaction value: $0
Shares: -338,282
Change %: -33%
Price: $0.000000
Shares after: 676,564
Date: 21 Feb 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 338,282 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 338,282 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.